What is PostEra?
PostEra offers advanced medicinal chemistry services, leveraging sophisticated machine learning algorithms to accelerate drug discovery and development. Founded in 2019 and headquartered in Massachusetts, the United States, PostEra is positioned at the intersection of pharmaceutical innovation and artificial intelligence. The company's approach aims to streamline the complex and time-consuming process of identifying and optimizing potential drug candidates, providing a crucial service to the biotechnology and pharmaceutical sectors.
How much funding has PostEra raised?
PostEra has raised a total of $92M across 2 funding rounds:
Series A
$24M
Corporate Investment
$68M
Series A (2022): $24M with participation from I2BF Global Ventures, HOF Capital, Metaplanets, ACE, Lifeforce Capital Gp I, The Pioneer Fund, The Clermont Group, R. Martin Chavez, and Breyer Capital
Corporate Investment (2022): $68M led by National Institutes of Health
Key Investors in PostEra
I2BF Global Ventures
I2BF Global Ventures is an international venture capital firm focused on technology, seeking innovative companies for a 'Brighter Future'. They manage over $195 million across four vehicles and have completed 24 transactions since 2006.
HOF Capital
HOF Capital is a global technology investment firm that utilizes its extensive limited partner network to support founders in building significant businesses.
National Institutes of Health
The National Institutes of Health (NIH) is the primary U.S. agency responsible for biomedical and health-related research, based in Bethesda, Maryland.
What's next for PostEra?
With substantial backing, PostEra is poised for accelerated growth and further development of its AI-driven platform. The recent influx of capital, particularly the major strategic investment, suggests a strong validation of its technology and market potential. This financing will likely fuel expansion of its research and development capabilities, enhancement of its machine learning models, and broader market penetration. PostEra's trajectory indicates a move towards scaling its operations and solidifying its position as a key player in the drug discovery services landscape, potentially enabling faster therapeutic breakthroughs.
See full PostEra company page
